This company listing is no longer active
Catalent Management
Management criteria checks 1/4
Catalent's CEO is Alessandro Maselli, appointed in Jul 2022, has a tenure of 2.42 years. total yearly compensation is $9.99M, comprised of 9.3% salary and 90.7% bonuses, including company stock and options. directly owns 0.021% of the company’s shares, worth €2.28M. The average tenure of the management team and the board of directors is 1.6 years and 9.3 years respectively.
Key information
Alessandro Maselli
Chief executive officer
US$10.0m
Total compensation
| CEO salary percentage | 9.3% |
| CEO tenure | 2.4yrs |
| CEO ownership | 0.02% |
| Management average tenure | 1.6yrs |
| Board average tenure | 9.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$413m |
| Jun 30 2024 | US$10m | US$925k | -US$1b |
| Mar 31 2024 | n/a | n/a | -US$1b |
| Dec 31 2023 | n/a | n/a | -US$1b |
| Sep 30 2023 | n/a | n/a | -US$1b |
| Jun 30 2023 | US$7m | US$925k | -US$256m |
| Mar 31 2023 | n/a | n/a | US$21m |
| Dec 31 2022 | n/a | n/a | US$389m |
| Sep 30 2022 | n/a | n/a | US$399m |
| Jun 30 2022 | US$3m | US$654k | US$483m |
| Mar 31 2022 | n/a | n/a | US$485m |
| Dec 31 2021 | n/a | n/a | US$561m |
| Sep 30 2021 | n/a | n/a | US$544m |
| Jun 30 2021 | US$5m | US$640k | US$529m |
| Mar 31 2021 | n/a | n/a | US$494m |
| Dec 31 2020 | n/a | n/a | US$289m |
| Sep 30 2020 | n/a | n/a | US$250m |
| Jun 30 2020 | US$3m | US$483k | US$173m |
| Mar 31 2020 | n/a | n/a | US$104m |
| Dec 31 2019 | n/a | n/a | US$124m |
| Sep 30 2019 | n/a | n/a | US$138m |
| Jun 30 2019 | US$2m | US$450k | US$132m |
Compensation vs Market: Alessandro's total compensation ($USD9.99M) is above average for companies of similar size in the German market ($USD4.83M).
Compensation vs Earnings: Alessandro's compensation has increased whilst the company is unprofitable.
CEO
Alessandro Maselli (52 yo)
2.4yrs
Tenure
US$9,985,363
Compensation
Mr. Alessandro Maselli has been President of Catalent Pharma Solutions, Inc. from February 2019 and serves as its Director since July 01, 2022 and is its Chief Executive Officer and was its Chief Operation...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.8yrs | US$5.28m | 0.024% € 2.6m | |
| President | 2.4yrs | US$9.99m | 0.021% € 2.3m | |
| Senior VP & CFO | 1.4yrs | US$6.65m | 0.0051% € 562.5k | |
| Senior VP & Chief Human Resources Officer | 1.3yrs | US$2.84m | 0.0030% € 328.5k | |
| President | 1.4yrs | US$1.55m | 0.0065% € 713.0k | |
| Group President of Biologics Segment | 1.3yrs | US$2.52m | 0.0024% € 263.7k | |
| VP & Chief Accounting Officer | less than a year | no data | no data | |
| Senior VP & Chief Information Officer | 4.6yrs | no data | 0.0060% € 659.2k | |
| Vice President of Investor Relations | 4.9yrs | no data | no data | |
| Senior VP | 1.8yrs | no data | 0.00093% € 102.2k | |
| Senior Vice President of Strategy & Corporate Development | 5.2yrs | no data | 0.013% € 1.4m | |
| Group President of Pharma & Consumer Health Segment | 5.9yrs | US$3.80m | 0.063% € 6.9m |
1.6yrs
Average Tenure
52yo
Average Age
Experienced Management: 0C8's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.8yrs | US$5.28m | 0.024% € 2.6m | |
| President | 2.4yrs | US$9.99m | 0.021% € 2.3m | |
| Independent Director | 9.1yrs | US$376.42k | 0.030% € 3.3m | |
| Independent Director | 10.3yrs | US$364.18k | 0.0061% € 670.2k | |
| Member of Advisory Board | 9.3yrs | no data | no data | |
| Independent Lead Director | 10.3yrs | US$439.57k | 0.015% € 1.7m | |
| Independent Director | 9.7yrs | US$400.12k | 0.00077% € 84.6k | |
| Independent Director | 9.4yrs | US$419.62k | 0.022% € 2.4m | |
| Member of Advisory Board | 9.7yrs | no data | no data | |
| Member of Advisory Board | 9.3yrs | no data | no data | |
| Member of Scientfic & Advisory Board | 9.3yrs | no data | no data | |
| Member of Advisory Board | 9.3yrs | no data | no data |
9.3yrs
Average Tenure
67yo
Average Age
Experienced Board: 0C8's board of directors are considered experienced (9.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/17 12:53 |
| End of Day Share Price | 2024/12/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Catalent, Inc. is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Sel Hardy | CFRA Equity Research |
| Parth Talsania | Equisights |